PRS20 - Budget Impact Analysis Of Budesonide In The Treatment Of Asthma In Adult Population In Russian Federation

Abstract

To conduct the budget impact analysis of Budesonide via Easyhaler and Turbuhaler devices, which could allows determining the net economic effect of the budget impact regarding in replacement the equal medication in one medical device to another. Information search was conducted in the public domain. Pharmacoeconomic analysis method – budget impact and direct cost analysis were performed. For reference, we accepted the exchange rate was 1 EUR = 83,44 RUB. In this study, the pharmacoeconomic evaluation was given for drugs Budesonide via Easyhaler and Turbuhaler. The study had a time horizon of one year. The daily dose of Budesonide was 800 mcg. Cost structure included following: the cost of basic pharmacotherapy, compensation costs for treatment of exacerbations, compensation costs for side effects and adverse events. The total direct cost per patient with asthma amounted to 70 098 RUB (840 EUR) to the Easyhaler group, 95 817 RUB (1 148 EUR) to the Turbuhaler group. The selection of budget impact method of pharmacoeconomic analysis was determined by the advantages of Budesonide Easyhaler in terms of its efficiency and lower value of total direct costs. In the present study, based on the results of the “cost analysis” it was revealed that the replacement Budesonide via Turbuhaler on Budesonide via Easyhaler saved per patient respectively 25 719 RUB (308 EUR) for the health care system budget. The budget impact analysis of Budesonide via Easyhaler device versus Budesonide via Turbuhaler device demonstrated that asthma treatment with Budesonide via Easyhaler can significantly save the budget.